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Neuronal function requires regulated anterograde and ret-
rograde trafficking of mitochondria along microtubules by
using the molecular motors kinesin and dynein. Previous
work has established that trafficking kinesin protein
(TRAK) 1 and TRAK2 are kinesin adaptor proteins that
link mitochondria to kinesin motor proteins via an
acceptor protein in the mitochondrial outer membrane,
the Rho GTPase Miro. Recent studies have shown that
TRAK1 preferentially controls mitochondrial transport in
axons of hippocampal neurons by virtue of its binding to
both kinesin and dynein motor proteins, whereas TRAK2
controls mitochondrial transport in dendrites resulting
from its binding to dynein. This study further investigates
the subcellular localization of TRAK1 and TRAK2 in pri-
mary cultures of hippocampal and cortical neurons by
using both commercial antibodies and anti-TRAK1 and
anti-TRAK2 antibodies raised in our own laboratory (in-
house). Whereas TRAK1 was prevalently localized in
axons of hippocampal and cortical neurons, TRAK2 was
more prevalent in dendrites of hippocampal neurons. In
cortical neurons, TRAK2 was equally distributed between
axons and dendrites. Some qualitative differences
were observed between commercial and in-house-
generated antibody immunostaining. VC 2015 Wiley Periodi-
cals, Inc.
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Twenty percent of the body’s resting energy is con-
sumed by the brain despite the brain being only 2% of the
body’s weight. This energy, in the form of ATP, is essen-
tial for correct neuronal function during synaptic and
action potential signaling in neurons (Attwell and Laugh-
lin, 2001). Because most brain ATP is generated by mito-
chondria, this implies that mitochondria must be spatially
adjacent to the sites of the ion influxes that generate syn-
aptic and action potentials. The main carbon source for
ATP production by mitochondria is glucose. Proper neu-
ronal metabolism is therefore dependent on a continuous
supply of glucose (Peppiatt and Attwell, 2004). Mito-
chondria are actively mobile in neurons, and it was
recently shown that mitochondrial dynamics are regulated
by glucose levels via the regulation of proteins associated
with mitochondrial transport (Pekkurnaz et al., 2014).
At any given time, 20–30% of the total mitochon-
dria population is mobile (Pilling et al., 2006; Kang et al.,
2008), so proper transport and targeting of mitochondria
from the cell body (where they are concentrated) into
dendrites and axons is essential for the function and sup-
port of synapses. Defective mitochondrial trafficking and
function are increasingly implicated in neurological dis-
eases (for review see Chan, 2006; Mattson et al., 2008).
In both axons and dendrites, the majority of mito-
chondrial transport is microtubule based. Mitochondria
undergo alternating outward (anterograde) and inward
(retrograde) transport. Their movement from neuronal
cell bodies into axonal and dendritic synaptic terminals is
regulated by a quaternary mitochondrial trafficking com-
plex. This is composed of the motor proteins kinesin or
dynein, the trafficking kinesin protein (TRAK) family of
kinesin adaptor proteins, the TRAK acceptor, the
mitochondrial outer membrane Rho GTPase Miro, and
the posttranslational modification enzyme N-
acetylglucosamine transferase (OGT; for review see Ste-
phenson and Brickley, 2011; Schwarz, 2013).
In mammals, there are two members of the TRAK
family, TRAK1 and TRAK2, whereas Drosophila has only
one TRAK gene, named Milton. TRAK1 and TRAK2
share an overall 48% amino acid identity and a 58% amino
acid sequence similarity (Beck et al., 2002; Iyer et al.,
2003). Both TRAK1 and TRAK2 are known to interact
with Miro (Glater et al., 2006).
Recently, it was reported that TRAK1 binds to
both kinesin and dynein motor proteins and that it is
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localized primarily in axons of hippocampal pyramidal
neurons in primary culture. In contrast, TRAK2 was
shown to interact predominantly with dynein, and it is
more abundant in dendrites compared with axons (van
Spronsen et al., 2013). These findings reflect those of pre-
vious studies in which trafficking assays in hippocampal
neurons were employed to show that kinesin motors spe-
cifically target axons and drive synaptic vesicle transport,
whereas the dynein/dynactin motor complex sorts postsy-
naptic receptors and Golgi outposts to dendrites (Zheng
et al., 2008; Kapitein et al., 2010). This study investigates
further the purported compartmentalization of TRAK1
and TRAK2, extending studies to their respective distri-
butions in both hippocampal and cortical primary cultures
by using both commercial antibodies and anti-TRAK1
and anti-TRAK2 antibodies raised in our own laboratory
(in-house).
MATERIALS AND METHODS
Constructs and Antibodies
The plasmids pEGFP-ratTRAK1 (pEGFP-rTRAK1),
pCis-rTRAK2, pDsRedTRAK1scrRNA, pDsRedTRA
K1shRNA, pGreenTRAK2scrRNA, and pGreenTRAK2s
hRNA were as described previously by Brickley and Stephen-
son (2011). Rabbit polyclonal anti-TRAK1 antibodies were
generated to the amino acid sequence Cys rat TRAK1 (973–
988) and affinity-purified by following standard protocols (Ste-
phenson and Duggan, 1991). Sheep anti-TRAK2 (874–889)
antibodies were generated as described by Brickley et al. (2005).
Anti-TRAK1 (catalog No. HPA005853), anti-TRAK2 (catalog
No. HPA015827), and anti-b-actin commercial antibodies
were purchased from Sigma Aldrich (Dorset, United Kingdom).
Mouse monoclonal anti-tau (tau-5) and antimicrotubule associ-
ated protein 2 (MAP2; HM-2) antibodies were purchased from
Abcam (Cambridge, United Kingdom). Goat anti-rabbit Alexa
Fluor 594 and 488, goat anti-sheep Alexa Fluor 594 and 488,
and goat anti-mouse Alexa Fluor 594 secondary antibodies were
from Life Technologies (Paisley, Scotland).
Mammalian Cell Transfections
Human embryonic kidney (HEK) 293 cells were trans-
fected with constructs by the calcium phosphate method by
using 1 lg total DNA/six-well plate. For double transfections,
a 1:1 ratio for a total of 2 lg DNA was used/six-well plate.
Cells were harvested 48 hr posttransfection and solubilized with
standard radioimmunoprecipitation assay buffer (1% [v/v] Tri-
ton X-100, 0.5% [w/v] Na-deoxylcholate, 0.1% [w/v] SDS,
150 mM NaCI, 1 mM EDTA, 10 mM NaF, 1 mM PMSF, 0.5
mg/ml protease inhibitor cocktail). For confocal studies, HEK
293 cells were transfected with constructs by the Lipofectamine
2000 (Life Technologies) method with 0.5 lg total DNA/24-
well plate. For double transfections, a 1:1 ratio for a total of 1
lg DNA was used/24-well plate.
Immunoblotting
Immunoblotting was carried out exactly as described by
Brickley et al. (2005) by using final antibody concentrations of
1 mg/ml anti-TRAK1 (973–988), 2 mg/ml anti-TRAK2 (874–
889), 0.2 mg/ml commercial anti-TRAK1, and 0.4 mg/ml com-
mercial anti-TRAK2.
Culturing and Transfection of Hippocampal
and Cortical Neurons
Cultures of rat hippocampal and cortical neurons were
prepared at a density of 30,000 cells/cm2 on poly-D-lysine (1
lg/ml)- and laminin (2 lg/ml)-coated coverslips from hippo-
campi or cerebral cortex dissected from E18 rat embryos by
standard methods (Goslin et al., 1998). Cultures were grown for
4–8 days in complete neurobasal media that consisted of neuro-
basal media (Life Technologies) containing a 1:50 dilution of
B27 (Life Technologies), 0.5 mM GlutaMax (Life Technolo-
gies), 0.4% (w/v) glucose, and 13 penicillin/streptomycin.
Transfection of neurons was by Lipofectamine LTX (Life Tech-
nologies). In brief, 24 hr prior to transfection, complete neuro-
basal medium with antibiotics was replaced by fresh complete
neurobasal medium without antibiotics. Subsequently, one-half
of the medium was removed and stored at 37C in 5% CO2.
The transfection reaction was performed according to the man-
ufacturer’s protocol. For all transfections, 0.5 lg EndoFree plas-
mid DNA was added per 24-well dish. After addition of the
transfection mixture, neurons were incubated at 37C in 5%
CO2, and the previously removed medium was then added.
Neurons were maintained at 37C in the presence of 5% CO2
until paraformaldehyde fixation (48–72 hr). For the short hair-
pin RNAi (shRNAi) knockdown studies, neuronal transfections
were carried out at 3–4 days in vitro (DIV), with paraformalde-
hyde fixation at 6–7 DIV.
Immunocytochemistry
Fixed cells (6–7 DIV) were permeabilized and blocked
with a solution containing 0.2% (v/v) Triton X-100 (Sigma)
and 10% (v/v) fetal bovine serum in phosphate-buffered saline
(PBS) for 1 hr at room temperature. Primary antibodies were
diluted in the solution to final concentrations of 10 mg/ml anti-
TRAK1 (973–988), 20 mg/ml anti-TRAK2 (874–889), 0.5 mg/
ml commercial anti-TRAK1, and 1.0 mg/ml commercial anti-
TRAK2, then added to the cells and incubated overnight at
4C. Cells were washed three times with PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4)
containing 0.1% (v/v) Tween 20 (Sigma) for 10 min with gentle
rotation. Secondary antibodies were added at a dilution five
times the concentration of the corresponding primary antibodies
and incubated for 1 hr at room temperature. Coverslips were
washed three times with PBS containing 0.1% (v/v) Tween 20
for 10 min with gentle rotation prior to fixation with 2% (w/v)
paraformaldehyde for 5 min at room temperature. After having
been washed an additional three times in PBS, coverslips were
mounted onto microscopy slides with 10 ll fluorescence
mounting solution (Dako, Agilent Technologies, Stockport,
United Kingdom). Nuclei were visualized by staining with 40,6-
diamidino-2-phenylindole (DAPI).
Confocal Microscopy and Image Analysis
Confocal microscopy was carried out with a Zeiss LSM
710 (Carl Zeiss, Oberkochen, Germany) confocal microscope
J_ID: z3p Customer A_ID: JNR23549 Cadmus Art: JNR23549 Ed. Ref. No.: 6094.R1 Date: 22-January-15 Stage: Page: 2
ID: padmavathym Time: 20:48 I Path: //xinchnasjn/01journals/Wiley/3B2/JNR#/Vol00000/140196/APPFile/JW-JNR#140196
2 Loss and Stephenson
Journal of Neuroscience Research
with oil immersion 340 or 363 objectives with sequential
acquisition setting. EGFP was excited with k5 488 nm at 2%
of intensity. Alexa Fluor 594 was excited with k5 561 nm at
2% intensity. Z-stacks of cells and neurons were taken at a reso-
lution of 1024 3 1024 pixels with the pinhole at a setting of 2
mm in the Zen Lite Blue software (Carl Zeiss), ensuring that
image saturation was not reached. Maximum projection inten-
sities were generated, and images were analyzed in ImageJ
(NIH). All cells and neurons were imaged as z-stacks, and max-
imum projection intensities were generated for image presenta-
tion. All experiments were from at least n5 20 neurons from at
least n5 3 cultured neuronal preparations.
For the analysis of antibody intensities in neurons, tau/
MAP2 counterstaining was used to distinguish between axons
and dendrites. Fluorophore intensities were determined in the
ImageJ plugin RGB profile (RGB_Profiler.java). To prevent
selection bias, cell bodies, axons, and dendritic segments were
selected in the red channel (tau or MAP2 immunoreactivities)
and quantified in the green channel (TRAK1 and TRAK2
immunoreactivities). The fluorescence intensities in axons and
dendrites were measured in segments of the same size and nor-
malized to the intensity of the cell bodies. To control for back-
ground fluorescence, the intensity adjacent to the axon or
dendrite was subtracted.
RESULTS
Comparison of the Epitopes Used To Generate
Anti-TRAK1 and Anti-TRAK2 Antibodies
In any microscopy/immunocytochemical study, the
specificity of the antibodies used is key, especially when
members of the same family of proteins share high per-
centages of amino acid identities. This is the case for
TRAK1 and TRAK2, which have 48% identity (Beck
et al., 2002). Thus, the immunogens that have been used
to generate anti-TRAK1 and anti-TRAK2 antibodies
were compared. These included TRAK1 and TRAK2
in-house antibodies, commercial antibodies, and those
used previously by van Spronsen et al. (2013) to study the
distribution of TRAK1 and TRAK2 in primary neurons.
The comparison of the immunogens is shown in Figure
F1 1.
For the commercial anti-TRAK1 and anti-TRAK2
antibodies, the antigens used for their generation were
fusion proteins corresponding to TRAK1 (238–470) and
TRAK2 (359–488). These regions share 37% amino
acid identity and 58% similarity and contain three
stretches of five, five, and 12 contiguous amino acid
sequences that are identical between TRAK1 and
TRAK2 (Fig. 1B). Similarly, fusion proteins were used
for the generation of anti-TRAK1 and anti-TRAK2 anti-
bodies by van Spronsen et al. (2013). The chosen sequen-
ces were from the TRAK1 and TRAK2 C-termini, i.e.,
TRAK1 (754–953) and TRAK2 (848–913). The C-
terminal domain is the least conserved region between
TRAK1 and TRAK2, but regions of amino acid identity
are still evident (Fig. 1B). Indeed, these fusion proteins
share 31% amino acid identity and 68% similarity. In
contrast, in-house antibodies were generated by using
short synthetic peptides corresponding to the noncon-
served C-terminal regions, i.e., TRAK1 (973–988) and
TRAK2 (874–889). Within these sequences, amino acid
identity is 33% and similarity is 69% but with a maximum
of two contiguous identical amino acids (Fig. 1B).
Characterization of Anti-TRAK1 and Anti-TRAK2
Antibodies
To assess the specificity of the various anti-TRAK1
and anti-TRAK2 antibodies, an shRNA gene knock-
down approach was used, followed by analysis of samples
by immunoblotting and immunocytochemistry.
Immunoblotting. HEK 293 cells were cotrans-
fected with pEGFP-rTRAK1 or pCis-rTRAK2 and
either the shRNA constructs pDsRedTRAK1shRNA
and pGreenTRAK2shRNA or the corresponding control
scrambled scr constructs, i.e., pDsRedTRAK1scrRNA or
pGreenTRAK2scrRNA (Brickley and Stephenson,
2011). For Western blot analyses, cell lysates were pro-
duced 48–72 hr posttransfection and analyzed with their
antibodies. (Note that HEK 293 cells do not express
endogenous TRAK1 and TRAK2 [Beck et al., 2002],)
In HEK 293 cells cotransfected with pEGFP-
rTRAK1 and either the scrRNA or the shRNA con-
structs, in-house anti-TRAK1 antibodies recognized a
major band with Mr 120 kDa, which corresponds to
the predicted molecular weight of pEGFP-rTRAK1 (Fig.
F22A). This Mr 120-kDa band was not detectable in cells
cotransfected with pCis-rTRAK2 and the scrRNA or
shRNA constructs, although a nonspecific band with Mr70 kDa was observed in all samples. HEK 293 cell
lysates cotransfected with pEGFP-rTRAK1 and pDsRed-
TRAK1shRNA showed a 47%6 16% (n5 3) reduction
in the Mr 120-kDa immunoreactive band with no
observed qualitative change in the Mr 70-kDa nonspe-
cific band (Fig. 2A). Similarly, anti-TRAK1 commercial
antibodies recognized TRAK1, i.e., Mr 120 kDa, in the
HEK 293 cell lysates, and this was decreased by 66%6 9%
(n5 3) in the presence of TRAK1 shRNA. However,
they also recognized a band that corresponds to the pre-
dicted size of pCis-rTRAK2, i.e., Mr 98 kDa, in samples
that were transfected with pCis-rTRAK2 and the
TRAK2 scrRNA or shRNAs. The percentage reduction
in signal for the Mr 98-kDa TRAK2 species was
38%6 7% (n5 3).
In HEK 293 cells cotransfected with pEGFP-
rTRAK2 and either the scrRNA or the shRNA con-
structs, in-house anti-TRAK2 antibodies recognized a
single band with Mr 98 kDa, which corresponds to the
predicted molecular weight of pCisTRAK2 (Fig. 2A). A
second minor band at Mr 110 kDa was also detected. No
band was visible in HEK 293 cells cotransfected with
pEGFP-rTRAK1 and corresponding shRNAs. The Mr
98-kDa band had an observed 29%6 8% (n5 3) reduc-
tion when immunoblots from pDsRedTRAK2shRNA
vs. pGreenTRAK2scrRNA cotransfectants were com-
pared (Fig. 2A). Similarly, commercial anti-TRAK2 anti-
bodies recognized TRAK2 with Mr 98 kDa in the
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Fig. 1. Comparison of the amino acid sequences used to generate
anti-TRAK1 and anti-TRAK2 antibodies. A: Amino acid sequences
of human TRAK1 and human TRAK2 with the amino acid sequen-
ces of the immunogens used for the generation of anti-TRAK1 (top)
and anti-TRAK2 (bottom) shown in the rectangles. Note that, for the
in-house anti-TRAK1 antibodies, a rat TRAK1 sequence was used,
but the equivalent aligned human TRAK1 sequence is shown. B:
Clustal Omega alignment of the immunogens used for the generation
of anti-TRAK1 and anti-TRAK2 antibodies. For in-house rTRAK1
antibodies, it is the rat sequence that is shown.
J_ID: z3p Customer A_ID: JNR23549 Cadmus Art: JNR23549 Ed. Ref. No.: 6094.R1 Date: 22-January-15 Stage: Page: 4
ID: padmavathym Time: 20:48 I Path: //xinchnasjn/01journals/Wiley/3B2/JNR#/Vol00000/140196/APPFile/JW-JNR#140196
4 Loss and Stephenson
Journal of Neuroscience Research
HEK 293 cells. A 32%6 13% (n5 3) decrease in this
band was detected in cells transfected with pCis-rTRAK2
and pGreenTRAK2shRNA compared with those trans-
fected with the pGreenTRAK2scrRNA control (Fig.
2A). However, as for the commercial anti-TRAK1 anti-
bodies, anti-TRAK2 antibodies also recognized a band
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corresponding to the molecular size of pEGFP-rTRAK1,
i.e., Mr 120 kDa, in HEK 293 cells transfected with
pEGFP-rTRAK1. The percentage reduction in signal for
the Mr 98-kDa TRAK2 species was 75%6 6% (n5 3). A
second band at Mr 85 kDa was also detected by com-
mercial anti-TRAK2 antibodies in the samples cotrans-
fected with both the TRAK1 and the TRAK2 constructs
and either the scrRNA or the shRNA. TableT1 I summa-
rizes the specificities of the anti-TRAK1 and anti-
TRAK2 antibodies.
Immunocytochemical analyses of HEK 293-
transfected cells. For the immunocytochemical stud-
ies, HEK 293 cells were fixed 48–72 hr posttransfection,
and immunostaining was performed with in-house and
commercial anti-TRAK1 and anti-TRAK2 antibodies.
Cells cotransfected with pEGFP-rTRAK1 and pDsRed-
TRAK1scrRNA stained with in-house anti-TRAK1
antibodies coupled with anti-rabbit Alexa Fluor 680
revealed immunostaining in HEK 293 cell bodies and a
higher expression in the perinuclear region and at the tip
of cellular processes, as previously described for both
TRAK1 and GFP-tagged TRAK1 (Fig. 2B; Brickley
et al., 2005, 2011). No fluorescence was evident in HEK
293 cells cotransfected with pEGFP-rTRAK1 and
pDsRedTRAK1shRNA and stained with in-house anti-
TRAK1 antibodies. Similar results were obtained with
regard to both distribution and specificity for commercial
anti-TRAK1 antibodies (Fig. 2B).
HEK 293 cells cotransfected with pCis-rTRAK2
and pGreenTRAK2scrRNA stained with in-house anti-
TRAK2 antibodies coupled with anti-rabbit Alexa Fluor
594 revealed similar patterns of fluorescence, as they did
for labeling with anti-TRAK1 antibodies; i.e., localization
was evident in cell bodies, but higher expression was
detected in the perinuclear region and at the tip of cellular
processes, again, as previously described for TRAK2 and
GFP-TRAK2 (Brickley et al., 2005, 2011). No fluores-
cence was evident in HEK 293 cells cotransfected with
pEGFP-rTRAK1 and pDsRedTRAK1shRNA and
stained with in house anti-TRAK2 antibodies (Fig. 2B).
Table I summarizes the specificities of the anti-TRAK1
and anti-TRAK2 antibodies.
Immunocytochemical analyses of endogenous
TRAK1 and TRAK2 in primary neuronal
cultures. To determine the specificity of the in-house
and commercial anti-TRAK antibodies in primary neuro-
nal cultures, 4-DIV hippocampal and 4-DIV cortical neu-
rons were transfected with pDsRedTRAK1shRNA,
pGreenTRAK2shRNA, or the corresponding scrambled
control shRNAs, i.e., pDsRedTRAK1scrRNA or
pGreenTRAK2scrRNA. Neurons were fixed 48–72 hr
posttransfection, and immunostaining was performed as
described in Materials and Methods.
All anti-TRAK1 and anti-TRAK2 antibodies
showed immunofluorescent staining in both primary hip-
pocampal (Fig. F33) and cortical (Fig. F44) neurons. Both in-
house and commercial antibodies showed similar profiles
for immunostaining for TRAK1 in cortical and hippo-
campal neurons and, similarly, for TRAK2 in cortical and
hippocampal neurons. Anti-TRAK1 immunoreactivity
was strongest in the perinuclear region. It was also distrib-
uted throughout the neurons, including axonal and den-
dritic processes. Anti-TRAK2 immunoreactivity was also
enriched in the perinuclear region, and, in addition, it
was distributed in the cytoplasm and dendritic and axonal
processes, although the labeling of processes was less clear
than was found for labeling with anti-TRAK1 antibodies.
It is noteworthy that an accumulation of both TRAK1
and TRAK2 immunoreactivities was noticed at the tips of
differentiating axons. This most likely coincides with the
growth cone of the axons.
Transfection of pDsRedTRAK1scrRNA or
pGreenTRAK2scrRNA had no effect on the expression
of TRAK1 or TRAK2 in both hippocampal and cortical
neurons. This can be seen in Figures 3 and 4, in which
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Fig. 2. Characterization of anti-TRAK1 and anti-TRAK2 in-house
and commercial antibodies by Western blotting and immunocyto-
chemistry. A: HEK 293 cells were cotransfected with pEGFP-
rTRAK11 pDsRedTRAK1shRNA (1), pEGFP-rTRAK11
pDsRedTRAK1scrRNA (2), pCis-rTRAK21 pGreenTRAK2sh
RNA (3), or pCis-rTRAK21 pGreen TRAK2scrRNA (4) cell lysates
prepared 24 hr posttransfection and analyzed by immunoblotting with
in-house or commercial anti-TRAK1, anti-TRAK2, or anti-b-actin
antibodies as shown as described in Materials and Methods. Arrows
indicate the positions of TRAK1 and TRAK2. Histograms show the
percentage expression of exogenous TRAK1 or TRAK2 with respect
to the scrRNA controls and are mean6 SEM for n5 3 independent
transfection experiments. B: HEK 293 cells were cotransfected with
pEGFP-rTRAK11 pDsRedTRAK1shRNA, pEGFP-rTRAK11 pD
sRedTRAK1scrRNA, pCis-rTRAK21 pGreenTRAK2shRNA, or
pCis-rTRAK21 pGreenTRAK2scrRNA and stained with the corre-
sponding anti-TRAK1 or anti-TRAK2 in-house or commercial anti-
bodies labeled as described in Materials and Methods. For all sets of
images, the image at left shows transfected cells stained with the in-
house and commercial anti-TRAK1 or anti-TRAK2 antibodies, the
center image shows the fluorescence of the transfected shRNA or
scrRNA constructs, and the image at right is the merged image for
each panel. Blue is DAPI nuclear staining. Images are representative
of at least n5 20 cells from at least n5 3 independent transfections.
Scale bars5 10 mm.
TABLE I. Summary of the Specificities of the Commercial and
In-House Anti-TRAK1 and Anti-TRAK2 Antibodies*
Immunoblot Immunofluorescence
Antibody TRAK1 TRAK2 TRAK1 TRAK2
TRAK1 in house 111 111
TRAK2 in house 11 111
TRAK1 commercial 11 1 11 1
TRAK2 commercial 1 11 1 111
*1 Indicates the relative specificity of the antibody, where 111 repre-
sents the highest specificity. For the immunofluorescence, the plus signs
correspond to immunofluorescent staining of HEK 293 cells expressing
either TRAK1 or TRAK2 (results not shown).
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Fig. 3. Immunostaining of hippocampal pyramidal neurons with in-
house and commercial anti-TRAK1 and anti-TRAK2 antibodies fol-
lowing gene knockdown with shRNAs. Primary cultures of hippo-
campal pyramidal neurons were transfected with pDsRedTRA
K1shRNA, pDsRedTRAK1scrRNA, pGreenTRAK2shRNA, or
pGreenTRAK2scrRNA at 3–4 DIV and stained with the correspond-
ing in-house (A) or commercial (B) anti-TRAK1 and anti-TRAK2
antibodies at 6–7 DIV as described in Materials and Methods. In all
cases, the image at left shows the fluorescence of the transfected
shRNA or scrRNA constructs, the center image shows staining with
in-house (A) or commercial (B) anti-TRAK1 or anti-TRAK2 anti-
bodies as labeled, and the image at right shows the merged image for
each. Blue is DAPI nuclear staining. Top panels show cell bodies and
bottom panels show selected axons; arrows highlight regions of
pGreen- or DsRed-positive axons where TRAK1 and TRAK2
expression can be compared between shRNA and scrRNA in trans-
fected vs. nontransfected neurons. Images are representative of at least
n5 20 hippocampal pyramidal neurons from at least n5 3 independ-
ent transfections. Scale bars5 10 mm.
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labeling of transfected cells can be compared with that of
neighbouring untransfected neurons (Fig. 3, right, for
TRAK1 and TRAK2 in hippocampal neurons; Fig. 4,
right, for TRAK1 and TRAK2 in cortical neurons).
shRNA knockdown of TRAK1 or TRAK2 had no appa-
rent effect on TRAK1 and TRAK2 in cell bodies and
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Fig. 4. Immunostaining of cortical neurons with in-house and com-
mercial anti-TRAK1 and anti-TRAK2 antibodies following gene
knockdown with shRNAs. Primary cultures of cortical neurons were
transfected with pDsRedTRAK1shRNA, pDsRedTRAK1scrRNA,
pGreenTRAK2shRNA, or pGreenTRAK2scrRNA at 3–4 DIV and
stained with the corresponding in-house (A) or commercial (B) anti-
TRAK1 and anti-TRAK2 antibodies at 6–7 DIV as described in
Materials and Methods. In all cases, the image at left shows the fluo-
rescence of the transfected shRNA or scrRNA constructs, the center
image shows staining with in-house (A) or commercial (B) anti-
TRAK1 or anti-TRAK2 antibodies as labeled, and the image at right
is the merged image for each. Blue is DAPI nuclear staining. Top
panels show cell bodies, and the bottom panels show selected axons;
arrows highlight regions of pGreen- or DsRed-positive axons where
TRAK1 and TRAK2 expression can be compared between shRNA
and scrRNA in transfected vs. nontransfected neurons. Images are rep-
resentative of at least n5 20 cortical neurons from at least n5 3 inde-
pendent transfections. Scale bars5 10 mm.
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dendrites of both hippocampal (Fig. 3, left) and cortical
(Fig. 4, left) neurons. However, when the axons of both
hippocampal and cortical neurons were analyzed, there
was a notable reduction in both TRAK1 and TRAK2
levels (Figs. 3, 4). In fact, TRAK1 and TRAK2 immu-
noreactivities were not detected in axons of neurons
transfected with pDsRedTRAK1shRNA or pGreen-
TRAK2shRNA, respectively. The discrepancy between
knockdown in axons vs. cell bodies and dendrites may be
due to high expression of endogenous TRAKs in these
compartments. The levels of anti-TRAK1 and anti-
TRAK2 immunoreactivities were similar when staining
patterns with in-house and commercial anti-TRAK1 and
anti-TRAK2 antibodies were compared (Figs. 3, 4).
Comparison of the Axonal and Dendritic
Distributions of TRAK1 and TRAK2 in Primary
Neuronal Cultures
A recent article reported that, in hippocampal
pyramidal neurons, TRAK1 is more prevalent in axons,
whereas TRAK2 is more abundant in dendrites (van
Spronsen et al., 2013). These researchers utilized in-house
antibodies raised against fusion proteins that had signifi-
cant amino acid sequence identity (Fig. 1). Although
some characterization of these in-house antibodies was
carried out, to corroborate the reported findings, the
immunocytochemical distributions of TRAK1 and
TRAK2 were carried out with our in-house and com-
mercial antibodies in 7-DIV primary hippocampal and
cortical neurons in conjunction with costaining with anti-
bodies directed against the axonal marker tau and the
dendritic marker MAP2.
FigureF5 5 shows the distribution of endogenous
TRAK1 and TRAK2 in conjunction with tau and MAP2
immunoreactivities in primary hippocampal (Fig. 5A) and
cortical (Fig. 5B) neurons. To determine the localization
of TRAK1 and TRAK2 in axons vs. dendrites, the fluo-
rescence intensities were determined in the ImageJ plugin
RGB_Profiler. The highest intensity of >20 axons and
>20 dendrites was measured and then normalized to the
highest intensity of TRAK1 and TRAK2 in the cell
bodies of the corresponding neurons. The normalized
intensity of axons was compared with the normalized
intensity of dendrites. For in-house and commercial anti-
bodies in hippocampal neurons, it was observed that
TRAK1 was expressed at approximately twice the level
in dendrites. The values were TRAK1 in dendrites com-
pared with axons 0.496 0.12 times (in-house antibodies,
hippocampal neurons) and 0.416 0.05 times (commercial
antibodies, hippocampal neurons). In cortical neurons, a
similar pattern was observed for TRAK1 immunoreactiv-
ity; i.e., TRAK1 expression in dendrites was 0.576 0.07
times that in axons. However, with commercial anti-
TRAK1 antibodies, an approximately equal distribution
between axons and dendrites was observed. For TRAK2,
a different distribution profile was seen. Thus, in hippo-
campal neurons for both in-house and commercial anti-
TRAK2 antibodies, TRAK2 was highest in dendrites vs.
axons. Values were 1.736 0.15 times (in house) and
1.546 0.10 times (commercial) for dendritic vs. axonal
distribution. In cortical neurons, there was an approxi-
mately equal distribution of TRAK2. This was the case
for both commercial and in-house anti-TRAK2
antibodies.
DISCUSSION
Because the brain is critically dependent on the supply of
energy generated by mitochondria, understanding how
they are trafficked to match requirements for function is
important. The TRAK family of kinesin adaptor proteins
are key mediators of mitochondrial transport. This study
investigated the use of antibodies, both generated in-
house and available commercially, to study the subcellular
distribution of the two members of this gene family,
TRAK1 and TRAK2, in two types of neurons in primary
culture, i.e., hippocampal pyramidal and cortical neurons.
A different distribution of TRAK1 and TRAK2 was evi-
dent between axons and dendrites and between the two
neuronal types. In hippocampal neurons, both commer-
cial and in-house antibodies yielded similar profiles, with
TRAK1 being more abundant in axons compared with
dendrites. By contrast, TRAK2 was expressed at higher
levels in dendrites compared with axons. In neurons of
cortical cultures, there was a discrepancy between com-
mercial and in-house antibodies and also TRAK1 and
TRAK2 subcellular compartmentalization. Whereas
TRAK1 was enriched in axons but equally distributed
between axons and dendrites with in-house antibodies, an
equidistribution between axons and dendrites for both
TRAK1 and TRAK2 was found for the localization with
commercial antibodies. These empirical observations sug-
gest that TRAK1 and TRAK2 do play distinct roles in
the regulation of mitochondrial transport and hence,
importantly, the delivery of a local supply of energy in
the brain.
There has been only one article to date describing
the subcellular distribution of TRAK1 and TRAK2 in
one neuronal cell type, i.e., hippocampal pyramidal neu-
rons at 14 DIV (van Spronsen et al., 2013). Although the
findings reported here are generally in agreement for this
neuronal type, i.e., for both in-house and commercial
antibodies TRAK1 being more abundant in axons vs.
dendrites and TRAK 2 vice versa, there are qualitative
and quantitative differences between the two studies. For
example, the percentage difference in distribution for
endogenous TRAK2 vs. TRAK1 in dendrites is more
marked in the van Spronsen et al. (2013) study; the
immunolabeling in neuronal processes is more punctate
than that described here (van Spronsen et al., 2013), and
intense TRAK1 immunoreactivity was observed in the
perinuclear region, which was less marked in the findings
of van Spronsen et al. (2013). These differences may be
attributed to developmental differences because in the
current study immunolabeling was carried out at 7 DIV
compared with 14 DIV by van Spronsen et al. (2013) or,
alternatively, because of antibody specificity. It was
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notable that, when hippocampal pyramidal neurons were
treated with the TRAK1 shRNA, a reduction in TRAK1
immunolabeling was observed in processes but not in cell
bodies (Fig. 4). This may be explained by high transcrip-
tion of TRAK1 resulting in a decreased efficiency of
knockdown, the stability of TRAK1 in processes, or,
alternatively, antibody specificity. The antibodies used in
this study were characterized in depth using specific gene
knockdown in conjunction with two experimental para-
digms, immunoblotting and immunocytochemical
C
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Fig. 5. Analysis of axonal and dendritic subcellular distribution of
TRAK1 and TRAK2 in hippocampal pyramidal and cortical neurons
with in-house and commercial anti-TRAK1 and anti-TRAK2 anti-
bodies. Primary cultures of hippocampal pyramidal neurons (A) or
cortical neurons (B) were costained with in-house (top) or commer-
cial (bottom) anti-TRAK1 (green) or anti-TRAK2 (green) and either
anti-tau (red) or anti-MAP2 (red) antibodies, with the distribution in
axons vs. dendrites quantified as described in Materials and Methods.
Arrows show representative examples for the codistribution of
TRAK1 or TRAK2 with either tau or MAP2 immunoreactivities.
The images are representative of at least n5 20 neurons. Histograms
show the quantitative results. The highest fluorescent intensity in
axons, normalized to the highest intensity of cell bodies, was set to a
value of 1 and compared with the highest intensity in dendrites, also
normalized against the highest intensity of cell bodies. Values for
TRAK1 in dendrites compared with axons are 0.496 0.12 (in-house
antibodies, hippocampal neurons) and 0.576 0.07 (in-house antibod-
ies, cortical neurons). For TRAK2, values in dendrites compared with
axons are 1.736 0.15 (in-house, hippocampal pyramidal neurons).
Quantitative results were analyzed by Student’s t-test, *P< 0.05,
**P< 0.01, ***P< 0.001. Scale bars5 10 mm.
J_ID: z3p Customer A_ID: JNR23549 Cadmus Art: JNR23549 Ed. Ref. No.: 6094.R1 Date: 22-January-15 Stage: Page: 10
ID: padmavathym Time: 20:50 I Path: //xinchnasjn/01journals/Wiley/3B2/JNR#/Vol00000/140196/APPFile/JW-JNR#140196
10 Loss and Stephenson
Journal of Neuroscience Research
analyses. It was observed that, although the commercial
antibodies recognized both TRAK1 and TRAK2 in
immunoblots, they had profiles similar to those of the
more selective in-house anti-TRAK1 and anti-TRAK2
antibodies with respect to distribution studies. There
were, however, quantitative differences between com-
mercial and-in house antibodies for axonal vs. dendritic
localization. TRAKs are key components of a quaternary
mitochondrial trafficking complex. Within this complex,
motor proteins, Miro, and OGT all bind TRAKs at dis-
tinct sites, so there is always the potential for steric hin-
drance with regard to antibody binding. This is pertinent
particularly for quantitative localization studies and sup-
ports the good practice of simultaneous use of antibodies
with different specificities.
It is unclear why there should be a difference in
TRAK1 distribution between axons and dendrites and,
also, in TRAK2 distribution between hippocampal
pyramidal and cortical neurons. where it was found to
have an equal distribution between axons and dendrites.
The observations vis-a-vis axonal vs. dendritic localization
may be due in part to the availability of the motor pro-
teins and the binding preferences of TRAK1 (kinesin pre-
ferring) and TRAK2 (dynein preferring) as proposed by
van Spronsen et al., (2013). It may, alternatively, be a
result of distinct developmental and overall expression
levels of TRAK1 vs. TRAK2. Similarly, this may explain
the differences between hippocampal vs. cortical neurons,
or the distinct distributions might reflect the energy
requirements of the different neuronal cell types. Further
studies are required to establish the contribution of
TRAK-mediated mitochondrial transport to its functional
significance in meeting brain energy requirements.
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